TRM-like CD8+ T cells can also provide local immune protection against tumor challenge, and TRM gene markers extracted from tumor-free tissues are significantly related to the improvement of clinical prognosis of TNBC patients treated with checkpoint inhibitors [38]. The gene discussed is CD8A; the disease is neoplasm.